Merck & Co. Financial Model
Pharmaceuticals Company Financials Example (Free Excel Download)
Merck & Co. (known as MSD outside the US and Canada) is a global healthcare company that discovers, develops, and provides innovative prescription medicines, biologic therapies, vaccines, and animal health products.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and scenario planning tool to assess how Merck & Co. will navigate the impending 2028 loss of exclusivity for its flagship oncology drug Keytruda, evaluating whether its late-stage pipeline and recent acquisitions can replace the anticipated revenue decline.
Merck & Co. (known as MSD outside the US and Canada) is a global healthcare company that discovers, develops, and provides innovative prescription medicines, biologic therapies, vaccines, and animal health products. The company operates a highly research-intensive business model focused on oncology, cardiometabolic diseases, and infectious diseases.
Business segments include:
- Pharmaceutical (approximately 89% of total revenue): Includes human health pharmaceuticals and vaccines, heavily dominated by the oncology blockbuster Keytruda and the HPV vaccine Gardasil.
- Animal Health (approximately 10% of total revenue): Discovers and develops veterinary pharmaceuticals and vaccines for both livestock and companion animals.
- Other Revenues (approximately 1% of total revenue): Alliance revenues and third-party manufacturing arrangements.
The company holds a dominant competitive position in immuno-oncology but faces significant concentration risk, with Keytruda accounting for nearly half of total sales. Recent major events include the $10.8 billion acquisition of Prometheus Biosciences in 2023, the acquisition of Harpoon Therapeutics in 2024, the launch of the pulmonary arterial hypertension drug Winrevair, and severe headwinds in the Chinese market for Gardasil throughout 2024 and 2025.
The downloadable Merck & Co. financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsMerck & Co. financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $48.70B | $59.28B | $60.12B | $64.17B | $65.01B |
| Gross profit | $35.08B | $41.87B | $43.99B | $48.98B | $48.63B |
| Cost of sales | $13.63B | $17.41B | $16.13B | $15.19B | $16.38B |
| Net income | $12.35B | $14.52B | $365.0M | $17.12B | $18.25B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Merck & Co.
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Pharmaceutical: Oncology (Keytruda)
- Segment name: Pharmaceutical (Oncology)
- Revenue driver formula: Total Addressable Patient Population x Market Share x Annual Treatment Cost x Compliance Rate
- Historical growth rate: 15% to 20% historically, slowing to 7% in 2025 ($31.7 billion).
- Key growth levers and headwinds: Growth is driven by approvals in earlier-stage indications (adjuvant and neoadjuvant settings) and the rollout of a subcutaneous formulation. The primary headwind is the impending loss of exclusivity in 2028 and inclusion in the US Inflation Reduction Act price negotiations starting in 2029.
- Pricing dynamics: High-priced biologic subject to intense scrutiny, mandatory European price cuts, and upcoming US Medicare price negotiations.
- Seasonality: Generally stable, though US purchasing patterns can cause slight quarterly fluctuations.
Pharmaceutical: Vaccines (Gardasil / Gardasil 9)
- Segment name: Pharmaceutical (Vaccines)
- Revenue driver formula: Target Demographic Population x Vaccination Rate x Price per Dose x Doses per Patient
- Historical growth rate: Highly volatile recently, dropping 39% in 2025 to $5.2 billion.
- Key growth levers and headwinds: Ex-China growth remains solid, but the franchise has been severely impacted by elevated inventory levels and weak demand in China, forcing a temporary pause in shipments.
- Pricing dynamics: Government tender pricing in many international markets; standard commercial pricing in the US.
- Seasonality: Stronger in the third quarter due to back-to-school vaccination campaigns in the Northern Hemisphere.
Pharmaceutical: Cardiometabolic & Respiratory (Winrevair)
- Segment name: Pharmaceutical (Cardiometabolic & Respiratory)
- Revenue driver formula: Diagnosed PAH Patients x Market Penetration x Net Price
- Historical growth rate: Launched recently, generating $1.4 billion in 2025.
- Key growth levers and headwinds: Rapid uptake in pulmonary arterial hypertension clinics is the primary growth lever.
- Pricing dynamics: Premium orphan-drug pricing model.
Animal Health
- Segment name: Animal Health
- Revenue driver formula: (Livestock Volume x Price) + (Companion Animal Volume x Price)
- Historical growth rate: 4% to 8% annually ($6.4 billion in 2025).
- Key growth levers and headwinds: Driven by the Bravecto line of products ($1.1 billion in 2025) and steady livestock demand.
- Pricing dynamics: Out-of-pocket consumer spending for companion animals; commercial agricultural pricing for livestock.
- Seasonality: Companion animal parasiticide sales peak in the spring and summer quarters.
Cost Structure
Variable Costs / COGS
- Breakdown: Manufacturing costs, raw materials, inventory step-up charges from acquisitions, and royalty payments on partnered products.
- Gross margin range: 71% to 77% over the last five years. GAAP gross margin was 74.8% in 2025, while Non-GAAP gross margin was approximately 77.2%.
- Key input costs: Active pharmaceutical ingredients, biologic manufacturing overheads, and third-party royalties.
- Scale dynamics: High operating leverage. Once manufacturing fixed costs are covered, incremental biologic sales carry margins exceeding 90%.
Operating Expenses
- R&D: Extremely high, typically 25% to 28% of revenue ($17.9 billion in 2025). This covers clinical trials, upfront payments for licensing deals, and early-stage research.
- SG&A: Typically 16% to 18% of revenue ($10.8 billion in 2025). Driven by global sales force headcount, marketing for new launches like Winrevair, and administrative overhead.
- Depreciation & Amortisation: Significant amortisation of intangible assets related to historical acquisitions (Schering-Plough, Prometheus, Harpoon).
- Restructuring: Frequent charges related to manufacturing footprint optimisation and pipeline reprioritisation ($309 million in Q4 2025 alone).
Margin Profile
- Gross margin: 74% to 77%.
- Operating margin: Highly volatile due to upfront R&D charges from acquisitions, ranging from 4% in 2023 (due to the Prometheus acquisition) to over 32% in 2025.
- Net margin: Typically 25% to 28% when excluding one-time acquisition charges.
Balance Sheet Structure
- Total assets: Approximately $129 billion.
- Key asset categories: Intangible assets and goodwill make up a massive portion of the balance sheet due to serial acquisitions. Cash and equivalents sit at approximately $14.6 billion.
- Working capital profile:
- DSO: Typically 60 to 70 days.
- DIO: Typically 80 to 100 days (biologics require long manufacturing lead times).
- DPO: Typically 45 to 60 days.
- Net working capital: Generally positive, tying up cash as the company grows.
- PP&E: Global manufacturing facilities, particularly biologic manufacturing plants for Keytruda and vaccines.
Capital Expenditure & Investment
- Capex as % of revenue: Typically 4% to 6% (approximately $4 billion annually).
- Maintenance vs. growth: Heavily skewed towards growth capex to build out biologic and vaccine manufacturing capacity.
- M&A pattern: Serial acquirer using a "string of pearls" strategy. The company frequently buys clinical-stage biotech firms (e.g., Prometheus for $10.8 billion, Harpoon for $680 million) to replenish its pipeline.
- Acquisition multiples: Often pays high premiums for pre-revenue biotech assets based on peak sales potential rather than trailing EBITDA.
Debt & Capital Structure
- Total debt: Approximately $49 billion ($46.8 billion long-term, $2.6 billion short-term).
- Net debt: Approximately $34.4 billion.
- Debt/EBITDA ratio: 0.9x to 1.9x depending on the metric used (GAAP vs Non-GAAP EBITDA).
- Key debt instruments: Senior unsecured notes and commercial paper.
- Interest rate profile: Predominantly fixed-rate long-term bonds. Interest expense is well covered by operating profit (interest coverage ratio near 29x).
- Share repurchase programme: Active buyer of its own shares, spending approximately $1.3 billion in Q4 2025 alone.
- Dividend policy: Strong dividend payer with a yield around 3.1% and a payout ratio typically between 40% and 50% of adjusted earnings.
Cash Flow Characteristics
- Operating cash flow conversion: Very strong. The company generated $16.5 billion in OCF in 2025.
- Free cash flow margin: Typically 15% to 20% of revenue ($12.4 billion in 2025).
- Major non-cash items: Massive depreciation and amortisation of acquired intangibles, stock-based compensation, and acquired in-process R&D charges.
- Working capital impact: Inventory build-ups for new product launches can be a significant use of cash.
- Cash tax rate: The effective non-GAAP tax rate is typically 13% to 15%, benefiting from international tax structures and R&D tax credits.
Sheet Structure
- Assumptions: Hardcoded drivers for macroeconomic inputs, tax rates, WACC, and segment-level growth rates.
- Pipeline & LOE Schedule: A dedicated sheet modelling Keytruda's patent cliff (2028-2030) and probability-weighted revenue for late-stage pipeline assets (e.g., subcutaneous Keytruda, MK-8690).
- Revenue Build: Detailed bottom-up forecast for Pharmaceutical (Keytruda, Gardasil, Winrevair, Capvaxive, Januvia) and Animal Health (Livestock, Companion Animal).
- Income Statement: Consolidated view mirroring the 10-K, separating GAAP and Non-GAAP adjustments (especially acquired IPR&D).
- Balance Sheet: Standard asset and liability forecasting, highlighting the large intangible asset base.
- Cash Flow Statement: Indirect method, bridging net income to OCF, investing (capex and M&A), and financing (dividends and buybacks).
- Debt Schedule: Tranche-by-tranche debt maturity profile and interest expense calculation.
- Working Capital: Schedules for accounts receivable, inventory, and accounts payable.
- DCF Valuation: Unlevered free cash flow build, terminal value calculation, and implied share price.
Key Financial Relationships
- `Keytruda Revenue = Prior Year Keytruda Revenue x (1 + Keytruda Growth Rate)`
- `Gardasil Revenue = Prior Year Gardasil Revenue x (1 + Gardasil Growth Rate)`
- `Winrevair Revenue = Prior Year Winrevair Revenue x (1 + Winrevair Growth Rate)`
- `Animal Health Revenue = Livestock Revenue + Companion Animal Revenue`
- `Total Revenue = Pharmaceutical Revenue + Animal Health Revenue + Other Revenues`
- `COGS = Total Revenue x (1 - Gross Margin %)`
- `R&D Expense = Total Revenue x R&D Margin %`
- `SG&A Expense = Total Revenue x SG&A Margin %`
- `Operating Income (Non-GAAP) = Total Revenue - COGS - R&D Expense - SG&A Expense`
- `Net Interest Expense = (Average Short-Term Debt x Short-Term Rate) + (Average Long-Term Debt x Long-Term Rate) - (Average Cash x Interest Yield)`
- `Tax Expense = Pre-Tax Income x Effective Tax Rate`
- `Free Cash Flow = Operating Cash Flow - Capital Expenditures`
Cross-Sheet Dependencies
- The Pipeline & LOE Schedule is the most critical driver, feeding directly into the Revenue Build to simulate the 2028 Keytruda patent cliff.
- The Revenue Build feeds the top line of the Income Statement and drives the activity in the Working Capital sheet.
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- The Cash Flow Statement determines the ending cash balance and borrowing needs, which feed the Debt Schedule and Balance Sheet.
- A circularity exists between the Debt Schedule (interest expense), the Income Statement (net income), and the Cash Flow Statement (cash available for debt paydown). A toggle must be included to break this circularity.
Sign Convention
- Revenue and Assets: Entered and displayed as positive numbers.
- Expenses (COGS, R&D, SG&A): Entered as positive numbers in the assumptions but subtracted in the Income Statement formulas.
- Cash Outflows (Capex, Dividends, Debt Repayment): Displayed as negative numbers on the Cash Flow Statement.
- Liabilities and Equity: Entered and displayed as positive numbers on the Balance Sheet.
Things Most Likely to Go Wrong
- Underestimating the Keytruda Cliff: Failing to model a steep enough revenue decline post-2028 will drastically overvalue the company. The model must include a specific LOE curve.
- Mishandling Acquired IPR&D: Merck frequently takes massive upfront charges for acquisitions (e.g., $10.8B for Prometheus). These distort GAAP earnings and must be added back to assess true operating cash flow.
- Gardasil China Exposure: Assuming historical growth rates for Gardasil will break the model. The 2025 baseline reflects a 39% decline due to China; future growth must be modelled off this lower, ex-China base.
- IRA Price Setting: Januvia and Keytruda are subject to US government price negotiations. The model must apply a step-down in US pricing for Keytruda starting in 2029.
- R&D Capitalisation: The builder might apply standard corporate R&D metrics, ignoring that pharma R&D is structurally higher (25-30% of sales) and includes upfront licensing payments.
- Gross Margin Distortion: Inventory fair value step-ups from acquisitions temporarily depress GAAP gross margins. The model should use Non-GAAP gross margins for long-term forecasting.
- Foreign Exchange Drag: Merck generates over half its revenue outside the US. The model should ideally forecast on a constant-currency basis or include an FX headwind assumption.
- Share Count Creep vs Buybacks: The company buys back shares, but issues equity for compensation. The net reduction in share count must be modelled accurately.
Validation Checks
- "Total Revenue growth should not exceed 5% annually in the near term, and must turn negative in 2029/2030 due to the Keytruda LOE."
- "Gross margin must remain between 74% and 77%; flag if it falls outside this band."
- "R&D expense must remain above 25% of total revenue to reflect the company's aggressive pipeline replenishment strategy."
- "Net Debt / EBITDA should remain below 2.0x to maintain the company's strong credit profile."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Free Cash Flow conversion (FCF / Net Income) should be greater than 80%."
- "Effective tax rate should remain between 13% and 16% based on historical global tax structures."
- "Dividend payout ratio should not exceed 60% of Non-GAAP Net Income."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Keytruda Revenue Growth (2026-2028) | 7.0 | % | Based on 2025 actual growth rate |
| Keytruda Revenue Growth (2029+) | -30.0 | % | Estimated impact of US LOE and IRA price setting |
| Gardasil Revenue Growth | 5.0 | % | Reflects ex-China stabilization after 2025's 39% decline |
| Winrevair Revenue Growth | 40.0 | % | Rapid uptake of new PAH launch |
| Animal Health Revenue Growth | 8.0 | % | Based on 2025 actual growth rate |
| Non-GAAP Gross Margin | 76.0 | % | Blended average of recent historical performance |
| R&D Expense Margin | 27.5 | % | Reflects heavy ongoing clinical trial investments |
| SG&A Expense Margin | 16.5 | % | Based on 2025 actuals |
| Effective Tax Rate | 14.5 | % | Based on 2025 Non-GAAP effective tax rate |
| Capex as % of Revenue | 5.0 | % | Historical average for manufacturing expansion |
| Dividend per Share (Annual) | 3.24 | $ | Based on recent quarterly run rate ($0.81/qtr) |
| Share Repurchases (Annual) | 5.0 | $B | Run rate based on recent quarterly activity |
| WACC | 7.5 | % | Standard discount rate for large-cap pharma |
| Terminal Growth Rate | 1.0 | % | Conservative long-term growth due to patent cliffs |
Data Sources & Benchmarks
- SEC Filings: Merck's Investor Relations page and SEC EDGAR database for 10-K and 10-Q filings.
- Key Peers: Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly (LLY), AstraZeneca (AZN), and Roche (ROG).
- Industry Data: EvaluatePharma for consensus pipeline NPVs and LOE impact curves; IQVIA for prescription volume data.
- Consensus Estimates: Visible Alpha or Bloomberg for sell-side consensus on Keytruda peak sales and Winrevair penetration rates.
Sources
Do more with the Merck & Co. model
Frequently asked
What does Merck & Co. do?+
Merck & Co. is a global healthcare company that discovers, develops, and provides innovative prescription medicines, biologic therapies, vaccines, and animal health products. It operates a highly research-intensive business model focused on oncology, cardiometabolic diseases, and infectious diseases.
What are Merck's primary revenue sources?+
Merck's primary revenue comes from its Pharmaceutical segment, heavily dominated by the oncology drug Keytruda and the HPV vaccine Gardasil, which accounts for approximately 89% of total revenue. The Animal Health segment contributes about 10% of revenue, with other revenues making up the remainder.
How does the financial model address the Keytruda loss of exclusivity?+
The financial model provides a comprehensive equity valuation and scenario planning tool to assess how Merck & Co. will navigate the impending 2028 loss of exclusivity for its flagship oncology drug Keytruda. It evaluates whether its late-stage pipeline and recent acquisitions can replace the anticipated revenue decline.
What is a key assumption for Merck's revenue growth in the financial model?+
A key assumption for Merck's revenue growth in the financial model is approximately 11.34%. This forecast extends over a horizon from FY2026 to FY2030, reflecting anticipated performance and strategic initiatives.
How does Merck & Co. manage its capital expenditures?+
Merck's capital expenditure typically ranges from 4% to 6% of revenue, amounting to approximately $4 billion annually. This spending is heavily skewed towards growth capex, particularly for building out biologic and vaccine manufacturing capacity.
Can I download an Excel financial model for Merck & Co.?+
Yes, a comprehensive Excel financial model for Merck & Co. is available for download. This model provides an equity valuation and scenario planning tool to analyze the company's future financial performance and key assumptions.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Pharmaceuticals Company Financial Models
Browse another company in the same sector.
AbbVie
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products.
Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on areas of high unmet medical need.
Biogen
Biogen is a global biotechnology company that discovers, develops, and delivers therapies for neurological, immunological, and rare diseases, including multiple sclerosis and Alzheimer's treatments.
Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative medicines in areas of unmet medical need.
Incyte
Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
Johnson & Johnson
Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices.
Lilly (Eli)
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and markets human medicines, with a dominant focus on cardiometabolic diseases, oncology, immunology, and neuroscience.
Explore more Healthcare financial model templates.
